Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
|Videos|August 17, 2021
Dr. Rohit Jain on factors affecting treatment selection in renal cell carcinoma
Author(s)Urology Times staff
Advertisement
Rohit Jain, MD, Moffitt Cancer Center, discusses risk status and other factors he considers in treatment selection for patients with advanced renal cell carcinoma (RCC).
Note: this interview was filmed before the
Advertisement
Related to this article
The approval is supported by data from the phase 3 LITESPARK-011 trial.
Advertisement
Advertisement
Trending on Urology Times
1
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
2
FDA updates in urology: September 2026
3
Enzalutamide plus salvage radiotherapy associated with improved PFS in high-risk BCR
4
SBRT, prostatectomy show comparable long-term disease control in PACE-A trial
5